These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 11192476)
1. Monitoring antiplatelet therapy: What is the best method? Mukherjee D; Moliterno DJ Clin Pharmacokinet; 2000 Dec; 39(6):445-58. PubMed ID: 11192476 [TBL] [Abstract][Full Text] [Related]
2. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy. Lippi G; Montagnana M; Danese E; Favaloro EJ; Franchini M Biomark Med; 2011 Feb; 5(1):63-70. PubMed ID: 21319966 [TBL] [Abstract][Full Text] [Related]
3. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. Berkowitz SD Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626 [TBL] [Abstract][Full Text] [Related]
4. Antiplatelet intervention in acute coronary syndrome. Arora RR; Rai F Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648 [TBL] [Abstract][Full Text] [Related]
5. The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines. Hostetter JC; Bhatt DL Minerva Cardioangiol; 2003 Oct; 51(5):531-46. PubMed ID: 14551522 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124 [TBL] [Abstract][Full Text] [Related]
7. Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. Schafer AI Tex Heart Inst J; 1997; 24(2):90-6. PubMed ID: 9205981 [TBL] [Abstract][Full Text] [Related]
10. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. Galli M; Maggioni AP; Vassanelli C; Tavazzi L Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377 [TBL] [Abstract][Full Text] [Related]
11. GP IIb/IIIa blockade during peripheral artery interventions. Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207 [TBL] [Abstract][Full Text] [Related]
13. [Antithrombocytic effectiveness of magnesium]. Gawaz M Fortschr Med; 1996 Sep; 114(26):329-32. PubMed ID: 8999005 [TBL] [Abstract][Full Text] [Related]
14. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care. Hankey GJ Cerebrovasc Dis; 2004; 17 Suppl 3():11-6. PubMed ID: 14730253 [TBL] [Abstract][Full Text] [Related]
15. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328 [TBL] [Abstract][Full Text] [Related]
16. [Platelet activation and inhibition. Old and new platelet antiaggregants]. López Bescós L; Jiménez Nacher JJ Rev Esp Cardiol; 1999; 52 Suppl 1():67-75. PubMed ID: 10364816 [TBL] [Abstract][Full Text] [Related]
17. Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. Jennings LK; Saucedo JF Curr Opin Cardiol; 2008 Jul; 23(4):302-8. PubMed ID: 18520712 [TBL] [Abstract][Full Text] [Related]
18. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861 [TBL] [Abstract][Full Text] [Related]